Ann: September Quarterly Activity and Cashflow Report, page-71

Some understandable concerns people are raising. However, we know that revenue from Pharma sales takes 3 months to hit. Last qtr was accurate and in line with initial sales (actually higher than I expected). The expenses are straight away, however, which is why we had an increase in expenses last quarter. Either way, sales and revenue are building well and we should see increases in the next few quarters. Cash burn is standard at this phase. Not sure why people would invest at this end of the market and complain about cash burn. We are not even that bad when you look at competitors. Either way, that is part of the risk when you invest at this phase, but you invest with the hope that it makes it. For me, with the fast growth and expansion across multiple continents, it is looking positive and I don't think it will be long before we are cashflow positive. GLTA Holders.